During the past decade, Hamamatsu Rosai Hospital conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 3 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hamamatsu Rosai Hospital" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator and "Boehringer Ingelheim" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Hamamatsu Rosai Hospital" are "Diabetes Mellitus, Type 2" (2 trials), "Idiopathic Interstitial Pneumonia" (1 trials) and "Refractory and/or Unexplained Chronic Cough" (1 trials). Many other conditions were trialed in "Hamamatsu Rosai Hospital" in a lesser frequency.

Most popular intervention types in "Hamamatsu Rosai Hospital" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "BAY1817080" (1 trials), "empagliflozin 10 mg" (1 trials), "empagliflozin 10 mg + linagliptin 5 mg" (1 trials) and "empagliflozin 25 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hamamatsu Rosai Hospital" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Hamamatsu Rosai Hospital". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Hamamatsu Rosai Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hamamatsu Rosai Hospital, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".